142 related articles for article (PubMed ID: 22323178)
1. Confounding factors in off-label drug use.
Greenberg PE; Pike C; Sisitsky T
Health Aff (Millwood); 2012 Feb; 31(2):460; author reply 460. PubMed ID: 22323178
[No Abstract] [Full Text] [Related]
2. Intended and unintended consequences of the gabapentin off-label marketing lawsuit among patients with bipolar disorder.
Chace MJ; Zhang F; Fullerton CA; Huskamp HA; Gilden D; Soumerai SB
J Clin Psychiatry; 2012 Nov; 73(11):1388-94. PubMed ID: 23146199
[TBL] [Abstract][Full Text] [Related]
3. False Claims Act prosecution did not deter off-label drug use in the case of neurontin.
Kesselheim AS; Darby D; Studdert DM; Glynn R; Levin R; Avorn J
Health Aff (Millwood); 2011 Dec; 30(12):2318-27. PubMed ID: 22147859
[TBL] [Abstract][Full Text] [Related]
4. Pfizer versus Kaiser: insurers want their day in court.
Silverman E
BMJ; 2013 Jun; 346():f3738. PubMed ID: 23760967
[No Abstract] [Full Text] [Related]
5. Dr. Vieta replies.
Vieta E
J Clin Psychiatry; 2013 Aug; 74(8):854. PubMed ID: 24021510
[No Abstract] [Full Text] [Related]
6. Apparent discrepancy between published study of gabapentin treatment and internal company report.
Mayo-Wilson E
J Clin Psychiatry; 2013 Aug; 74(8):853-4. PubMed ID: 24021509
[No Abstract] [Full Text] [Related]
7. Compromising the medical literature: the hidden influence of industry-biased articles.
Fugh-Berman A; Siwek J
Am Fam Physician; 2011 Sep; 84(5):489-90. PubMed ID: 21888299
[No Abstract] [Full Text] [Related]
8. Drug maker to pay $430 million in fines, civil damages.
FDA Consum; 2004; 38(4):36-7. PubMed ID: 15346583
[TBL] [Abstract][Full Text] [Related]
9. Diabetic peripheral neuropathic pain: is gabapentin effective?
Hyatt JD; Daniel D; Tran QV; Millares M; Kubota DR
Am Fam Physician; 2011 Sep; 84(5):480, 482; author reply 482. PubMed ID: 21888297
[No Abstract] [Full Text] [Related]
10. Off-label marketing stirs a legal hornet's nest.
Guglielmo WJ
Med Econ; 2006 Oct; 83(19):47-9. PubMed ID: 17066854
[No Abstract] [Full Text] [Related]
11. Implementation of a publication strategy in the context of reporting biases. A case study based on new documents from Neurontin litigation.
Vedula SS; Goldman PS; Rona IJ; Greene TM; Dickersin K
Trials; 2012 Aug; 13():136. PubMed ID: 22888801
[TBL] [Abstract][Full Text] [Related]
12. Seeding trials and the subordination of science.
Alexander GC
Arch Intern Med; 2011 Jun; 171(12):1107-8. PubMed ID: 21709112
[No Abstract] [Full Text] [Related]
13. Reporting of trials of gabapentin.
Gordh TE; Jensen TS; Kalso E
N Engl J Med; 2010 Apr; 362(17):1641; author reply 1641-2. PubMed ID: 20427815
[No Abstract] [Full Text] [Related]
14. FDA approves gabapentin prodrug as restless legs treatment.
Thompson CA
Am J Health Syst Pharm; 2011 May; 68(10):862. PubMed ID: 21546634
[No Abstract] [Full Text] [Related]
15. Gabapentin and tinnitus relief.
Shulman A
Int Tinnitus J; 2008; 14(1):1-5. PubMed ID: 18616079
[No Abstract] [Full Text] [Related]
16. [Gabapentin in the treatment of ocular neuromyotonia].
Porta-Etessam J; Parejo-Carbonell B; Gómez-Vicente L; Marcos-De Vega MA
Rev Neurol; 2009 Mar 16-31; 48(6):332-3. PubMed ID: 19291663
[No Abstract] [Full Text] [Related]
17. Evidence, regulation and 'rational' prescribing: the case of gabapentin for neuropathic pain.
Ghinea N; Lipworth W; Kerridge I
J Eval Clin Pract; 2015 Feb; 21(1):28-33. PubMed ID: 24986307
[TBL] [Abstract][Full Text] [Related]
18. Gabapentin and Pregabalin for Pain - Is Increased Prescribing a Cause for Concern?
Goodman CW; Brett AS
N Engl J Med; 2017 Aug; 377(5):411-414. PubMed ID: 28767350
[No Abstract] [Full Text] [Related]
19. What does the future hold for patients with epilepsy?
Faught E
Lancet Neurol; 2012 Apr; 11(4):298-300. PubMed ID: 22377179
[No Abstract] [Full Text] [Related]
20. Long-term effect of gabapentin in stiff limb syndrome: a case report.
Holmøy T
Eur Neurol; 2007; 58(4):251-2. PubMed ID: 17851249
[No Abstract] [Full Text] [Related]
[Next] [New Search]
